Weight-Loss Pill Wegovy Arrives in France

A tablet version of the weight-loss drug Wegovy has become available in France, offering patients an alternative to the injectable form that has been used until now. The pill format is expected to make the treatment more accessible to people who are uncomfortable with needles.

Wegovy is part of a group of medicines known as GLP-1 agonists, which work by suppressing appetite and slowing digestion. Originally developed to treat type 2 diabetes, these drugs have become increasingly popular as weight-loss treatments, driven by growing public demand and high-profile media attention.

The commercial market for GLP-1 medicines has expanded rapidly in recent years, turning them into one of the most talked-about categories in the pharmaceutical industry. However, this growth has been accompanied by a rise in reported adverse effects, ranging from digestive problems to more serious complications, prompting closer scrutiny from health authorities.

A new survey has found that nearly one in five people in France would be willing to take a GLP-1 drug specifically to lose weight, a figure that has alarmed public health specialists. Experts warn that this level of interest suggests the drugs may increasingly be sought by people without a clear medical need, rather than only by those diagnosed with obesity or related conditions.

Health professionals have expressed concern that widespread, casual use of these medicines could increase the risk of unmonitored side effects, particularly when patients obtain the drugs without proper medical supervision. They are calling for stronger public guidance on the appropriate use of GLP-1 treatments, as well as clearer communication about their risks and limitations.

As the pill version of Wegovy becomes more widely available, authorities are likely to face increasing pressure to balance patient access with safety, ensuring that the drug's growing popularity does not outpace proper regulation of its use.